| Trial ID | NCT04883255 |
| Status | Recruiting |
| Condition | HIV-1-infection |
| Intervention | 10 mg Δ9-tetrahydrocannabinol (THC) |
This trial addresses a critical knowledge gap in HIV care where cannabis use is widespread but poorly understood clinically. Given cannabis’s documented anti-inflammatory properties and HIV’s chronic inflammatory burden, understanding cognitive effects could inform evidence-based prescribing recommendations for this vulnerable population.
This observational study (NCT04883255) is examining how 10mg THC affects cognition and endocannabinoid system function in people with HIV-1 infection. The trial is currently recruiting participants to assess cognitive performance, decision-making, and biomarkers of endocannabinoid activity. Primary endpoints include neuropsychological testing and inflammatory markers, with secondary measures examining risk-taking behaviors and attention.
“If this trial demonstrates cognitive benefits at therapeutic THC doses, it could provide the evidence base I need to confidently recommend specific cannabis formulations for HIV patients experiencing cognitive symptoms. Currently, I’m prescribing based on limited data and patient reports rather than controlled evidence.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is this HIV and THC trial trying to find out?
The study, registered as NCT04883255, is examining how a 10 mg dose of THC affects cognition and the function of the endocannabinoid system in people with HIV-1 infection. The article describes it as an observational study, with 10 mg delta-9-tetrahydrocannabinol (THC) listed as the intervention.
Is this HIV and THC trial still enrolling participants?
Yes. The trial is listed with a status of recruiting, and the article states it is currently recruiting participants with HIV-1 infection. Because enrollment is still under way, its questions about how THC affects cognition in this group remain open for now.
What outcomes will researchers measure in the HIV and THC trial?
The primary endpoints are neuropsychological testing and inflammatory markers. Secondary measures look at risk-taking behaviors and attention. The trial is also assessing cognitive performance, decision-making and biomarkers of endocannabinoid activity in people with HIV-1 infection.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
